Literature DB >> 18054709

Influence of the Trp64Arg polymorphism in the beta 3 adrenoreceptor gene on insulin resistance, adipocytokine response, and weight loss secondary to lifestyle modification in obese patients.

D A de Luis1, M Gonzalez Sagrado, R Aller, O Izaola, R Conde.   

Abstract

BACKGROUND: The aim of our study was to investigate the influence of the Trp64Arg polymorphism in the beta 3 adrenoreceptor gene on adipocytokine response, insulin resistance, and weight loss secondary to lifestyle modification (Mediterranean hypocaloric diet and exercise) in obese patients.
METHODS: A population of 65 obese (BMI >30) non-diabetic outpatients was analyzed in a prospective way. Before and after 3 months of a lifestyle modification program, indirect calorimetry, bioimpedance, blood pressure, serial assessment of nutritional intake for 3 days via written food records, and biochemical analysis were performed. The lifestyle modification program consisted of a hypocaloric diet (1520 kcal, 52% carbohydrates, 25% lipids, and 23% proteins). The exercise program consisted of an aerobic exercise at least three times a week (60 min each). The statistical analysis was performed for Trp64/Arg64 and Arg64/Arg64 combined as a mutant group and for type Trp64/Trp64 as a wild group.
RESULTS: The mean age of the study participants was 45.8+/-16.8 years and the mean BMI was 34.4+/-4.6 kg. There were 18 males (27.7%) and 47 females (72.3%). Fifty-five patients (84.6%; 15 males/40 females) had the Trp64/Trp64 genotype (wild group) and ten patients (15.4%; 3 males/7 females) had Trp64/Arg64 (mutant group). In the wild group, BMI, weight, fat mass, systolic blood pressure and waist circumference decreased. In this group, resting metabolic rate (RMR), RMR corrected by fat free mass, and VO(2) increased. In the mutant group, BMI, weight, fat mass, and waist circumference decreased. A significant increase was detected in RMR and VO(2) as well. No differences were detected between baseline values in the two groups. CRP levels were higher in the mutant group than in the wild variants. No differences were detected in other parameters. Only leptin levels decreased significantly in both the wild group (10.1%; p<0.05) and the mutant group (13.6; p<0.05).
CONCLUSION: This study showed that the beneficial effect of mild weight reduction by a low caloric diet and exercise program is the greatest in subjects with a normal homozygote beta 3 adrenoreceptor gene.

Entities:  

Year:  2007        PMID: 18054709     DOI: 10.1016/j.ejim.2007.04.019

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  4 in total

1.  Beta-3-adrenergic receptor Trp64Arg polymorphism: does it modulate the relationship between exercise and percentage of body fat in young adult Japanese males?

Authors:  Hiroshi Nakashima; Kazuyuki Omae; Tetsuo Nomiyama; Yuko Yamano; Toru Takebayashi; Yutaka Sakurai
Journal:  Environ Health Prev Med       Date:  2013-01-06       Impact factor: 3.674

2.  A paleolithic diet is more satiating per calorie than a mediterranean-like diet in individuals with ischemic heart disease.

Authors:  Tommy Jönsson; Yvonne Granfeldt; Charlotte Erlanson-Albertsson; Bo Ahrén; Staffan Lindeberg
Journal:  Nutr Metab (Lond)       Date:  2010-11-30       Impact factor: 4.169

3.  Gene-diet-related factors of hyperglycaemia in postmenopausal women.

Authors:  Bogna Grygiel-Górniak; Elżbieta Kaczmarek; Maria Mosor; Juliusz Przysławski; Jerzy Nowak
Journal:  J Appl Genet       Date:  2018-02-20       Impact factor: 3.240

4.  Associations between Dietary Patterns, ADRβ2 Gln27Glu and ADRβ3 Trp64Arg with Regard to Serum Triglyceride Levels: J-MICC Study.

Authors:  Hinako Nanri; Yuichiro Nishida; Kazuyo Nakamura; Keitaro Tanaka; Mariko Naito; Guang Yin; Nobuyuki Hamajima; Naoyuki Takashima; Sadao Suzuki; Yora Nindita; Michiko Kohno; Hirokazu Uemura; Teruhide Koyama; Satoyo Hosono; Haruo Mikami; Michiaki Kubo; Hideo Tanaka
Journal:  Nutrients       Date:  2016-09-06       Impact factor: 5.717

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.